FDA clears Gilead's hepatitis D drug, four years after prior rejection
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distrib...
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distribution. The drug, known generically as bulevirtide, treats chronic hepatitis ...